Eaton Vance Management Vertex Pharmaceuticals Inc Transaction History

Eaton Vance Management

$67.5 Billion
Q3 2022

A detailed history of Eaton Vance Management transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Eaton Vance Management holds 451,027 shares of VRTX stock, worth $208 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares

451,027

Previous 449,691 0.3%

Holding current value

$208 Million

Previous $127 Million 3.05%

% of portfolio

0.19%

Previous 0.18%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $365,836 - $408,188	1,336 Added 0.3%	451,027 $131 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $1.22 Million - $1.52 Million	5,182 Added 1.17%	449,691 $127 Million
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $12.3 Million - $14.5 Million	55,553 Added 14.28%	444,509 $116 Million
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $8.98 Million - $11.3 Million	-50,755 Reduced 11.54%	388,956 $84.5 Million
Q3 2021 Nov 15, 2021	SELL	$181.39 - $202.99 $45.4 Million - $50.8 Million	-250,320 Reduced 36.28%	439,711 $79.3 Million
Q2 2021 Aug 16, 2021	SELL	$187.49 - $221.1 $26.2 Million - $30.9 Million	-139,687 Reduced 16.84%	690,031 $139 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $6.83 Million - $7.97 Million	-33,012 Reduced 3.83%	829,718 $178 Million
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $7.96 Million - $10.6 Million	38,468 Added 4.67%	862,730 $204 Million
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $3.06 Million - $3.63 Million	-11,969 Reduced 1.43%	824,262 $224 Million
Q2 2020 Nov 20, 2020	SELL	$225.48 - $295.8 $39,233 - $51,469	-174 Reduced 0.02%	836,231 $243 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $9.73 Million - $12.8 Million	-43,157 Reduced 4.91%	836,405 $243 Million
Q1 2020 May 14, 2020	SELL	$199.77 - $247.81 $6.45 Million - $8 Million	-32,269 Reduced 3.54%	879,562 $209 Million
Q4 2019 Feb 11, 2020	SELL	$166.71 - $223.91 $25.4 Million - $34.2 Million	-152,561 Reduced 14.33%	911,831 $200 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $34.1 Million - $38.4 Million	205,262 Added 23.89%	1,064,392 $180 Million
Q2 2019 Nov 21, 2019	BUY	$164.61 - $190.37 $7,407 - $8,566	45 Added 0.01%	859,130 $158 Million
Q2 2019 Aug 16, 2019	SELL	$164.61 - $190.37 $6.95 Million - $8.04 Million	-42,241 Reduced 4.69%	859,085 $158 Million
Q1 2019 May 14, 2019	SELL	$163.73 - $194.7 $900,023 - $1.07 Million	-5,497 Reduced 0.61%	901,326 $166 Million
Q4 2018 Feb 07, 2019	BUY	$151.91 - $192.21 $891,863 - $1.13 Million	5,871 Added 0.65%	906,823 $150 Million
Q3 2018 Nov 13, 2018	BUY	$167.73 - $192.74 $10.6 Million - $12.2 Million	63,266 Added 7.55%	900,952 $174 Million
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $27.2 Million - $31.7 Million	186,461 Added 28.63%	837,686 $142 Million
Q1 2018 May 07, 2018	BUY	$151.6 - $177.13 $399,314 - $466,560	2,634 Added 0.41%	651,225 $106 Million
Q4 2017 Feb 12, 2018	BUY	$137.28 - $155.55 $149,360 - $169,238	1,088 Added 0.17%	648,591 $97.2 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $95.9 Million - $105 Million	647,503	647,503 $98.4 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eaton Vance Management, based on Form 13F filings with the SEC.

News

Stay updated on Eaton Vance Management with notifications on news.

Account

Eaton Vance Management Vertex Pharmaceuticals Inc Transaction History